Title: Presenters: Date: Proportion of Newly Diagnosed Non-Small Cell Lung Cancer Patients That Would Have Been Eligible for Lung Cancer Screening Division.

Slides:

Advertisements

Similar presentations

Joseph J. Muscato, MD, FACP Medical Director Stewart Cancer Center, Boone Hospital.

Advertisements

The Role of Computed Tomography (CT) Screening for Lung Cancer Recommendations from the American College of Chest Physicians and the American Society of.

4.6 Assessment of Evaluation and Treatment 2013 Analytic Lung Cancer.

Clinical Solutions for Lung Cancer Screening (LCS)

The Downside of a Cancer Study Extolling CT Scans Tara Parker-Pope NYT – November 15, 2010

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER CROI 2015: Hot Topics in HIV Primary Care Brian R. Wood, MD Assistant Professor of Medicine, University.

How, Who, What Happens Next? Betty C. Tong, MD, MHS Division of Cardiovascular and Thoracic Surgery Co-Director, Lung Cancer Screening Program Duke University.

Screening for Lung Cancer Jess Dalehite, M.D. Southwest Medical Imaging Midland Memorial Hospital.

Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.

AJCC Staging Moments AJCC TNM Staging 7th Edition Lung Case #3 Contributors: Valerie W. Rusch, MD Memorial Sloan-Kettering Cancer Center, New York, New.

Lung Cancer Morbidity in Baltimore City & Chicago By Calandra Dyson Lyliane Mbah MoniQue Veney Promise Okafor.

TYPES, CAUSES, SYMPTOMS, TREATMENTS, STATISTICS, & PICTURES HEATHER XXXXXXX, 1 ST PERIOD Lung Cancer 1

Suzanne Lenz Wendy Oliver Caitlyn MacGlaflin, Sarah McDougall, Melissa Friedman.

Cervical Cancer in California Janet Bates, MD MPH Research Program Director Research and Surveillance Program California Cancer Registry.

Factors Associated with Bilateral vs. Unilateral Mastectomy in a Diverse, Population-based Sample of Breast Cancer Patients Sarah T. Hawley, PhD, MPH University.

Sonam Maghera 3 BSc, Sudhir Sundaresan 1,2 MD, P James Villeneuve 1,2 MD PhD, Andrew J Seely 1,2 MD PhD, Donna E Maziak 1 MD MSc,, Farid M Shamji 1 MD,

Lung Cancer 101 Carissa Thompson RN, BSN, OCN. Dispelling the myths O “Only smokers get Lung cancer” O “More women die from Breast cancer than from Lung.

Finding N.E.M.O. Marvin R. Balaan, MD, FCCP System Division Director, Division of Pulmonary and Critical Care Medicine Allegheny Health Network, Pittsburgh.

Lung Cancer Screening with Low Dose Computed Tomography Todd Robbins, MD Co-Director, Multidisciplinary Thoracic Oncology Program.

Slide 1 Barriers and Facilitations to HIV Testing in Private Care Settings Michael Horberg, MD MAS FACP Director, HIV/AIDS Kaiser Permanente Clinical Lead,

Implications of lung cancer screening in the new millenia Andrew R. Haas, MD, PhD Assistant Professor of Medicine Section of Interventional Pulmonary and.

Early Detection of Lung Cancer & Beyond

Multiple Arterial Bypass Grafting Should Be Routine Robert F Tranbaugh, David J Lucido, Kamellia R Dimitrova, Darryl M Hoffman, Charles M Geller, John.

on behalf of the ACOSOG Z4032 Investigators

Implications of lung cancer screening in the new millenia Andrew R. Haas, MD, PhD Assistant Professor of Medicine Section of Interventional Pulmonary and.

Adjuvant Radiation is Not Associated with Improved Survival in Patients with Positive Margins Following Lobectomy for Stage I & II Non-Small Cell Lung.

Lung Cancer Screening: Benefits and limitations to its Implementation

Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Intermittent vs Continuous Pulse Oximetry McCulloh R, Koster M, Ralston S, et al.

Grace Scott, MSc 1, Dr. Hosam Amoodi, MD 2, Dr. Damian Micomonaco, MD 2 1 Graduate Program in Health and Rehabilitation Sciences, _Western University 2.

[Insert Organization Name] Making the Case for Lung Cancer Screening.

Crizotinib outcomes in ALK- positive advanced NSCLC patients with brain metastases 1 RTI Health Solutions, Research Triangle Park, NC/United States of.

Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.

REDUCED LUNG-CANCER MORTALITY WITH LOW-DOSE COMPUTED TOMOGRAPHIC SCREENING The National Lung Screening Trial Research Team N Engl J Med 2011;365:

Date of download: 5/28/2016 From: Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S.

CT Screening for Lung Cancer vs. Smoking Cessation: A Cost-Effectiveness Analysis Pamela M. McMahon, PhD; Chung Yin Kong, PhD; Bruce E. Johnson; Milton.

Decoding the USPSTF By: Dr Vikram Arora Heritage Valley Health System.

Incidence of Abnormal Ankle-Brachial Index in Diabetic Patients Asymptomatic of Arteriosclerotic Vascular disease Brintha Vasagar, MD, MPH, Katee Castleman,

Rosemary D. Cress, DrPH Research Program Director Collection and Use of Industry and Occupation Data II: Overview and Goals NAACCR: June 19-25, 2010 Quebec.

Cancer Education Day Lung Cancer Screening Update Kirenza Francis, MD, FRCPC, DABR Windsor Radiological Associates May 13, 2016.

CHEST 2014; 145(4): 호흡기내과 R3 박세정. Cigarette smoking ㅡ the most important risk factor for COPD in the US. low value of FEV 1 : an independent predictor.

Sex-specific trends in lung cancer incidence and survival : a population study of cases 호흡기 내과 R3 조주희 Thorax 2011;66: Camilla M T Sagerup,

Pulmonary Embolism in Patients with Unexplained Exacerbation of COPD: Prevalence and Risk Factors Isabelle Tillie-Leblond, MD, PhD; Charles-Hugo Marquette,

Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Obstructive Lung Disease and Low Lung Function in.

Tobacco/Lung Cancer Working Group Participating Institutions: Case Western Reserve University; University of Washington; University of Iowa; University.

Template ID: junglegreens Size: 36x48 Impact of Hepatitis C Screening in Outpatient Population Madhuri Chandnani MD, Pallavi Pothuri MD, Michael Stevens.

Research Brief: Genetic Testing for Hereditary Cancers Craig Morse BIO 101 SNHU.

How Do We Individualize Guidelines in an Era of Personalized Medicine? Douglas K. Owens, MD, MS VA Palo Alto Health Care System Stanford University, Stanford.

Making the Case for Lung Cancer Screening

. Troponin limit of detection plus cardiac risk stratification scores for the exclusion of myocardial infarction and 30-day adverse cardiac events in ED.

From: Use of Decision Models in the Development of Evidence-Based Clinical Preventive Services Recommendations: Methods of the U.S. Preventive Services.

From: Screening for Lung Cancer With Low-Dose Computed Tomography: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation.

Prognosis of younger patients in non-small cell lung cancer

Background & Objectives

Lung Cancer Screening:

Making the Case for Lung Cancer Screening

Augmented Meaningful Use Criteria to Identify Patients Eligible for Lung Cancer Screening Dan J. Raz, MD, Rachel Dunham, NP, Brian Tiep, MD, Argelia.

Trends in Subpopulations at High Risk for Lung Cancer

Lung Cancer Screening Sandra Starnes, MD Professor of Surgery

Cigarette Smoking Associated With Lung Adenocarcinoma In Situ in a Large Case- Control Study (SFBALCS) Paige M. Bracci, PhD, Jennette Sison, MPH, Helen.

Joshua E. Rosen, BASc, Michelle C

Telomere Length and Recurrence Risk after Curative Resection in Patients with Early- Stage Non–Small-Cell Lung Cancer: A Prospective Cohort Study Eric.

Stamatia Destounis, MD, FACR, FSBI, FAIUM

Perceptions and Utilization of Lung Cancer Screening Among Primary Care Physicians Dan J. Raz, MD, MAS, Geena X. Wu, MD, Martin Consunji, BS, Rebecca.

Variations in Receipt of Curative-Intent Surgery for Early-Stage Non–Small Cell Lung Cancer (NSCLC) by State Helmneh M. Sineshaw, MD, MPH, Xiao-Cheng.

Rebuttal From Dr Mazzone

Volume 155, Issue 1, Pages (January 2019)

Trends in survival from metastatic lung cancer in California,

The clinical stage of non–small cell lung cancer as assessed by means of fluorodeoxyglucose–positron emission tomographic/computed tomographic scanning.

Lobectomy Versus Limited Resection in T1N0 Lung Cancer

Presentation transcript:

Title: Presenters: Date: Proportion of Newly Diagnosed Non-Small Cell Lung Cancer Patients That Would Have Been Eligible for Lung Cancer Screening Division of Thoracic Surgery City of Hope National Medical Center Duarte, CA Geena X. Wu, MD; Leanne Goldstein, DrPH; Jae Y. Kim, MD; Dan J. Raz, MD

Disclosures Leanne Goldstein: Rockwell Medical, Inc Dan Raz: Cireca, LLC

Introduction Lung cancer screening (LCS) guidelines among major health organizations. LCS criterion Other (NLST derived)USPSTFCMS NCCNAATS PrimarySecondaryPrimarySecondary Age (years) Smoking History (pack-years) ≥30 ≥20≥30≥20 Quit time (years)15 none Other criteria---- Additional risk factor - Additional risk factor ↑ lung cancer risk ≥5% in 5 years American Lung Association. Detterbeck FC. Chest 2013;143(5 Suppl):e78S-92S. Jaklitsch MT1. JTCVS 2012;144(1): Jensen T. Memo: CMS Report No.: CAG-00439N. Smith RA. CA Cancer J Clin 2014;64(1):30-51 Wood DE. J NCCN 2012;10(2) Moyer VA. Ann Intern Med 2013.

Methods 2,244 adults with NSCLC 2,030 NSCLC patients with complete smoking history Current smokers 630 (31%) Former smokers 873 (43%) Never smokers 527 (26%) 214 patients with unknown or incomplete smoking status or history Retrospective institutional cohort ( ) Text-mining and manual review of EMR Final cohort Excluded from analysis Patients with history of malignancy 442 (22%) Identified in cancer registry Secondary LCS criteria Primary LCS criteria

Results: Applying USPSTF LCS Criteria Current smokers n=873 Former smokers N=630 Mean age (years)6369 Median pack- years smoked4630 Median quit- time (years)-15 LCS criteria met, n (%) All Age Pack-year Quit time 425 (67.5) 480 (76.2) 524 (83.2) (31.3) 685 (78.5) 497 (56.9) 440 (50.4) All 31.8% 26.9% 16.4% 40.7% 45.0% 36.6% 35.0% 29.2% 45.6% 26.5%

Results: Applying USPSTF LCS Criteria Current smokers n=873 Former smokers N=630 Mean age (years)6369 Median pack- years smoked4630 Median quit- time (years)-15 LCS criteria met, n (%) All Age Pack-year Quit time 425 (67.5) 480 (76.2) 524 (83.2) (31.3) 685 (78.5) 497 (56.9) 440 (50.4) M F 45.0% 36.6% 35.0% 29.2% 45.6% 26.5% 13.1% 5.8%

Results: Applying USPSTF LCS Criteria All criteria met n=698 (34.4%) +6.6% +9.3% +23.0% Exclude quit time n=832 (41.0%) Exclude quit time and age n=887 (43.7%) Exclude quit time and pack-year n=1,165 (57.4%)

Results: Comparing LCS Criteria

Discussion Summary –A third of NSCLC patients met all LCS criteria –Only half of former smokers met quit time criterion Limitations –Generalizability of data –Retrospective application of LCS to NSCLC patients –Inability to determine timing or benefit of LCS Future Directions –Prospective assessment of utility of current LCS criteria, especially the quit time maximum –Consensus on a uniform, validated set of criteria to promote LCS

Title: Presenters: Date: Thank You